Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 27 min ago
Peer-reviewedCC BYMedicine

Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report

  • Jing Zhang1
  • Chun-Qiao Chen1
  • Hui Huang1
  • Zhi-Chao Yao2
  • Xi Qin3
  • Fei-Fei Wei4
4 affiliations
  1. 1Department of Oncology, People’s Hospital of Guilin, Guilin, Guangxi Zhuang Autonomous Region, China
  2. 2Department of Pathology, People’s Hospital of Guilin, Guilin, Guangxi Zhuang Autonomous Region, China
  3. 3Department of Oncology, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
  4. 4Department of Tumor Radiotherapy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region (The Second People’s Hospital of Guangxi Zhuang Autonomous Region), Guilin, Guangxi Zhuang Autonomous Region, China.
Read full textPDFCite

Related

  1. Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Shuaihang Chen, Shanshan Chen, Yuanqiang Li +6
    PeerJPeer-reviewedCC BY 4.0Full textImmunologyOncologyCrossrefPMC
  2. FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study
    Katharina Pomej, Adrian Frick, Bernhard Scheiner +23
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textGeneral medicineCrossref
  3. Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors.
    Hilal Karakaş, Safa Can Efil, Burak Bilgin +4
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  4. ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with bevacizumab and sintilimab therapy
    Minjun Liao, Xiaoxiao Wang, Zilong Wang +8
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJ
  5. Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Martina Milella, Francesco Lasorsa, Monica Rutigliano +5
    CellsPeer-reviewedCC BY 4.0OncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{zhang2026longterm,
  title = {{Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report}},
  author = {Jing Zhang and Chun-Qiao Chen and Hui Huang and Zhi-Chao Yao and Xi Qin and Fei-Fei Wei},
  journal = {Medicine},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13657458},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report
AU  - Jing Zhang
AU  - Chun-Qiao Chen
AU  - Hui Huang
AU  - Zhi-Chao Yao
AU  - Xi Qin
AU  - Fei-Fei Wei
PY  - 2026
DA  - 2026/10/09
JO  - Medicine
UR  - https://europepmc.org/article/PMC/PMC13657458
SN  - 0304-5412
SN  - 1536-5964
ER  -